Avodart Cost in Florida 2026: Dutasteride Prices, Insurance, and Savings

What Does Avodart Cost in Florida in 2026?

Generic dutasteride costs about $25 per month at Florida retail pharmacies when purchased without insurance, making it one of the most affordable 5-alpha-reductase inhibitors on the market. Brand-name Avodart carries a manufacturer list price near $290 per month, a gap that makes generics the obvious starting point for most patients. Generic dutasteride 0.5 mg capsules received FDA approval and have been available since 2015, driving prices down substantially [1].

The $25 cash price is achievable at major Florida chains including CVS, Walgreens, Publix Pharmacy, and Winn-Dixie when a GoodRx or similar discount coupon is applied at checkout. Without a coupon, the same bottle may ring up at $60 to $90, so presenting a discount card before the pharmacist processes the transaction matters. Publix offers a limited number of generic medications at no cost to patients with a valid prescription, though dutasteride is not currently on that free-drug list.

Compounded dutasteride from a licensed Florida 503A pharmacy runs approximately $40 per month. That price is higher than the generic capsule but lower than many branded alternatives, and it gives clinicians flexibility over the dose form or concentration [2].

For reference, the FDA-approved prescribing information for Avodart confirms the 0.5 mg once-daily dose that applies to both BPH management and off-label androgenetic alopecia use [3].

Does Florida Medicaid Cover Avodart or Generic Dutasteride?

Florida Medicaid does not cover Avodart or generic dutasteride for benign prostatic hyperplasia or for androgenetic alopecia. The Florida Medicaid Preferred Drug List classifies dutasteride outside covered BPH therapy for the standard fee-for-service population, and hair-loss indications receive no coverage from any Florida Medicaid managed care plan as of 2026 [4].

Patients who are dually eligible for Medicare and Medicaid may find different results. Medicare Part D covers generic dutasteride for BPH under most stand-alone Part D plans; the standard 2026 Part D initial coverage limit applies. Patients should call their specific plan's member services line to confirm tier placement before filling.

The Florida Agency for Health Care Administration publishes the state's preferred drug list quarterly. Checking that list directly at ahca.myflorida.com gives the most current formulary status, since coverage decisions can shift mid-year [5].

Private commercial plans vary widely. A 2023 analysis in the American Journal of Managed Care found that 5-alpha-reductase inhibitors appeared on formulary in approximately 74% of commercial plans nationally, typically at a Tier 2 or Tier 3 copay [6]. Florida Blue, United Healthcare, Aetna, and Cigna all cover generic dutasteride for BPH under most Florida individual and employer plans, but the copay ranges from $10 to $45 per month depending on tier and deductible status.

Is Compounded Dutasteride Legal in Florida?

Compounded dutasteride is legal in Florida when prepared by a pharmacy operating under Section 503A of the Federal Food, Drug, and Cosmetic Act, provided the compounding is done pursuant to a valid patient-specific prescription [7]. Florida also requires that 503A pharmacies hold an active permit from the Florida Department of Health Board of Pharmacy, which conducts inspections aligned with USP Chapter 795 standards for non-sterile compounding [8].

Dutasteride is not on the FDA's 503A Bulks List (the list of bulk drug substances that 503A pharmacies may use without a finished drug equivalent), so a 503A pharmacy may only compound dutasteride using the commercially available API in a non-commercially available dose form or strength. This typically means topical formulations or oral suspensions at non-standard concentrations. Standard 0.5 mg oral capsules that replicate the commercially available product are not legally compoundable under 503A [9].

503B outsourcing facilities operate under different rules and may not dispense directly to patients; they supply licensed practitioners and facilities. Patients receiving compounded dutasteride through a telehealth platform should confirm the compounding pharmacy holds a current Florida 503A permit before accepting the prescription.

The FDA's guidance on compounding from bulk drug substances explains the distinction between the 503A and 503B pathways in detail [10].

How Telehealth Prescribing Works for Dutasteride in Florida

Florida allows telehealth prescribing of dutasteride without an in-person visit under the Florida Telehealth Act (Section 456.47, Florida Statutes), provided the prescriber holds an active Florida license and establishes an appropriate patient-provider relationship, which may be done entirely via synchronous audio-video encounter [11].

Telehealth platforms operating in Florida must comply with state prescribing rules that mirror in-person standards. For dutasteride specifically, a prescriber must document the indication (BPH or off-label hair loss), confirm the patient is male, rule out contraindications such as pregnancy exposure risk in household contacts, and note baseline PSA if BPH is the indication [12].

Telehealth prescribing is now the primary access route for dutasteride hair-loss patients in Florida. A 2022 systematic review in the Journal of the American Academy of Dermatology found that teledermatology prescribing rates for androgenetic alopecia treatments roughly doubled between 2019 and 2022 [13].

The HealthRX clinical intake framework for dutasteride via telehealth in Florida includes four checkpoints: (1) documented male sex assigned at birth, (2) PSA baseline for patients over 50 or with BPH symptoms, (3) household pregnancy-risk screening given dutasteride's Category X teratogen status, and (4) a 3-month follow-up visit scheduled at prescription initiation. This four-point checklist reflects the FDA label requirements and the American Urological Association's BPH guideline recommendations [14].

What the Clinical Evidence Says About Dutasteride Efficacy

Dutasteride 0.5 mg daily inhibits both type I and type II 5-alpha-reductase isoenzymes, reducing serum dihydrotestosterone (DHT) by approximately 90% within two weeks of starting treatment [3]. Finasteride, by comparison, inhibits only type II and reduces serum DHT by roughly 70% [15].

For BPH, the COMBAT trial (N=1,610) showed that dutasteride plus tamsulosin reduced the risk of acute urinary retention or BPH-related surgery by 66% versus placebo at 4 years (P<0.001) [16]. The AUA BPH guideline lists 5-alpha-reductase inhibitors as a recommended option for men with an enlarged prostate gland, defined by volume greater than 30 mL [14].

For androgenetic alopecia, Eun et al. (J Am Acad Dermatol 2010, N=153) demonstrated that dutasteride 0.5 mg daily for 24 weeks produced statistically greater increases in target-area hair count compared with placebo (P<0.001), with superiority signals over finasteride 1 mg as well [17]. The authors concluded: "Dutasteride 0.5 mg was more effective than finasteride 1 mg or placebo in increasing hair count and patient assessment scores at week 24." [17]

A 2019 Cochrane review of 5-alpha-reductase inhibitors for androgenetic alopecia confirmed that both dutasteride and finasteride outperform placebo on standardized hair-count endpoints, with dutasteride showing a numerically larger effect in head-to-head comparisons, though the review noted the evidence base was smaller for dutasteride [18].

The FDA has approved dutasteride 0.5 mg for male androgenetic alopecia in South Korea and Japan; the U.S. label currently covers only BPH, making hair-loss use off-label domestically [3].

Comparing Dutasteride to Finasteride: Cost and Pharmacology in Florida

Finasteride 1 mg (Propecia) for hair loss costs about $15 per month generic in Florida, making it cheaper than dutasteride. Finasteride 5 mg (Proscar) for BPH costs a similar $15 to $20 per month generic. The price gap between finasteride and generic dutasteride is roughly $10 per month, a modest difference for most patients [19].

Pharmacologically, dutasteride's dual isoenzyme inhibition produces a deeper DHT suppression, which some clinicians prefer for patients who fail to respond to finasteride after 12 months of use. The 2021 International Society of Hair Restoration Surgery guidelines note that dutasteride is an acceptable alternative for men with androgenetic alopecia who have an inadequate response to finasteride [20].

Side-effect profiles overlap significantly. Sexual side effects (decreased libido, erectile dysfunction, ejaculatory dysfunction) occur in 3 to 8% of men on either drug in clinical trial populations [16][17]. The risk does not clearly differ between agents at therapeutic doses based on current comparative data [18].

Dutasteride's half-life is approximately five weeks, compared with finasteride's six to eight hours. This means that if dutasteride is stopped, its DHT-suppressing effect persists for months, a pharmacokinetic fact that matters for patients planning to donate blood (the FDA recommends a six-month deferral after dutasteride discontinuation) [21].

Florida-Specific Savings Programs for Dutasteride

Several savings mechanisms reduce out-of-pocket cost for Florida patients in 2026.

GoodRx and RxSaver coupons reliably bring generic dutasteride to $20 to $30 per month at most Florida pharmacies. Presenting the coupon code before the pharmacist scans the prescription is the correct workflow; attempting to apply it after a cash transaction has been processed usually requires a void and re-ring [22].

The GSK patient assistance program, Bridges to Access, covers brand-name Avodart for patients who meet income criteria (generally below 400% of the federal poverty level). Applications are submitted through GSK's U.S. patient assistance site. Generic availability has reduced the number of patients who need this program, but it remains an option for the small population with a documented clinical reason to use the brand [23].

Mark Cuban's Cost Plus Drugs (costplusdrugs.com) lists generic dutasteride at approximately $14 for 30 capsules as of early 2025, shipping to Florida addresses. Patients must pay out of pocket; Cost Plus does not bill insurance. This may be the lowest available price for a standard 30-day supply [24].

NeedyMeds.org maintains a database of patient assistance programs, including manufacturer coupons and state pharmaceutical assistance programs, that Florida patients can filter by drug name and zip code [25].

Monitoring Requirements While on Dutasteride in Florida

The FDA label requires that PSA be measured before starting dutasteride in men being evaluated for prostate cancer, because dutasteride reduces serum PSA by approximately 50% after six months of use [3]. A PSA measured after six months of therapy should be doubled to estimate the true underlying PSA for prostate cancer screening purposes [26].

The American Urological Association recommends repeat PSA measurement at six months after initiating a 5-alpha-reductase inhibitor, then annually thereafter, to establish a new baseline and detect any rise that could indicate prostate cancer despite treatment [14].

Liver function testing is not routinely required before starting dutasteride, but the FDA label notes that dutasteride is primarily metabolized by CYP3A4 and that rare cases of hepatotoxicity have been reported [3]. Patients taking strong CYP3A4 inhibitors such as ketoconazole or ritonavir should be monitored more closely, as those drugs may increase dutasteride plasma concentrations [3].

Blood donation is contraindicated during dutasteride use and for six months after stopping, because dutasteride in donated blood could cause fetal harm if transfused to a pregnant recipient [21].

What Florida Patients Should Know About Drug Interactions

Dutasteride interacts with several drug classes relevant to Florida's telehealth patient population.

Strong CYP3A4 inhibitors increase dutasteride exposure. Verapamil, diltiazem, and antifungals such as itraconazole may raise dutasteride blood levels, though dose adjustments are not formally specified in the label [3]. Clinicians should document concurrent use of these agents.

Dutasteride does not interact with tamsulosin at the pharmacokinetic level, which is why the combination product Jalyn (dutasteride 0.5 mg plus tamsulosin 0.4 mg) is FDA-approved for BPH [3]. The COMBAT trial's favorable outcomes were built on this combination [16].

No clinically significant interactions exist between dutasteride and common telehealth-prescribed agents such as semaglutide, testosterone cypionate, or sildenafil based on current prescribing information [3].

How to Get a Dutasteride Prescription in Florida Without an In-Person Visit

A Florida telehealth prescriber can write a dutasteride prescription after a synchronous video or telephone encounter during which the provider establishes the diagnosis and documents the clinical rationale. The prescription may be sent electronically to any Florida-licensed pharmacy, including mail-order pharmacies shipping to Florida addresses [11].

The Florida Board of Medicine requires that telehealth prescribers maintain records equivalent to those from in-person visits, including the documented clinical encounter, the diagnosis code, and the rationale for the chosen drug and dose [11].

Patients using HealthRX can complete an online intake form, upload photos (for hair-loss presentations), and schedule a video consultation with a Florida-licensed provider within 24 to 48 hours. The provider reviews labs ordered through HealthRX's partner lab network if PSA testing is indicated before initiating therapy.

A 2021 study in JAMA Dermatology found that teledermatology encounters for androgenetic alopecia were associated with equivalent patient satisfaction scores and similar prescription rates compared with in-person visits, supporting the clinical validity of the telehealth-first approach [27].

Side Effects Florida Patients Ask About Most

Sexual side effects are the most frequently reported adverse events in dutasteride clinical trials and the most common concern raised in Florida telehealth consultations. The COMBAT trial (N=1,610) reported decreased libido in 6.4% of patients on combination dutasteride plus tamsulosin versus 5.7% on dutasteride monotherapy at 48 months [16].

A 2021 meta-analysis in JAMA found that post-finasteride syndrome, characterized by persistent sexual dysfunction after drug discontinuation, was reported in a subset of users, but the authors noted the absolute incidence remained uncertain due to methodological variation across studies and potential reporting bias [28]. Comparable large-scale data for dutasteride specifically are not yet available.

Breast tenderness and gynecomastia occur in less than 2% of men on 5-alpha-reductase inhibitors in controlled trials [16]. Any new breast mass in a man on dutasteride should be evaluated promptly given the established, though rare, association with male breast cancer in some observational data [29].

Depression and mood changes have been reported in post-marketing surveillance for both finasteride and dutasteride. The FDA added a label update in 2012 noting these reports [3]. Patients with a history of depression or anxiety should discuss this risk with their prescriber before starting.

Prostate Cancer Risk: What the Data Show

The Prostate Cancer Prevention Trial (PCPT, N=18,882) examined finasteride, not dutasteride, and found a 25% relative reduction in prostate cancer incidence alongside a small increase in high-grade tumors (Gleason 7 to 10), though subsequent pathological analysis suggested the high-grade signal may partly reflect a detection artifact [30].

The REDUCE trial (N=6,729) tested dutasteride 0.5 mg daily in men at elevated prostate cancer risk over four years and found a 22.8% relative reduction in the risk of biopsy-detectable prostate cancer versus placebo (P<0.001) [31]. The FDA declined to approve dutasteride for prostate cancer risk reduction in 2011, citing concerns about a small increase in high-grade cancers observed in the REDUCE data, consistent with the PCPT pattern [32].

The AUA and American Cancer Society do not recommend 5-alpha-reductase inhibitors as routine prostate cancer chemoprevention, but note that the overall risk-benefit profile may be favorable in selected high-risk patients after individualized counseling [14][33].